Please login to the form below
liso-cel
This page shows the latest liso-cel news and features for those working in and with pharma, biotech and healthcare.
FDA approves BMS’ blood cancer CAR T therapy after delay
The US Food and Drug Administration (FDA) has finally approved Bristol Myers Squibb’s (BMS) CAR T-cell therapy Breyanzi, previously known as liso-cel, after delaying the decision in November
Latest news
-
FDA delays BMS’ liso-cel decision, citing COVID-19 travel restrictions
BMS picked up liso-cel 9 (lisocabtagene maraleucel) following its $74bn takeover of Celgene last year – the CAR-T therapy is one of the key assets critical to the potential payout ... We are committed to bringing liso-cel to patients with relapsed or
-
BMS suspends new clinical trials as COVID-19 cases rise in US
That decision won’t however affect its two most advanced clinical programmes – idecabtagene vicleucel (ide-cel or bb2121) for multiple myeloma and B-cell lymphoma therapy lisocabtagene maraleucel (liso-cel, JCAR017) – ... cancer – due 15 May –
-
FDA begins speedy review of BMS’ CAR-T liso-cel
Prior to the takeover, Celgene had forecast that liso-cel could become a $3bn product, dependent on regulatory approval. ... If it does receive approval, liso-cel will come onto the market after rival Novartis’ Kymriah (tisangenlecleucel) and Gilead
-
Celgene drugs drive BMS to a buoyant Q4, but Opdivo stalls
franchise headed by liso-cel for B-cell lymphomas – sets the company up well for the future.
-
Gilead owes BMS millions after losing Yescarta patent infringement trial
BMS acquired liso-cel from its $6bn takeover of Celgene – prior to being acquired, Celgene had put the CAR-T at becoming a potentially $3bn product. ... Gaining approval for liso-cel is a critical compenent on the payout of BMS’ takeover of Celgene,
More from news
Approximately 2 fully matching, plus 8 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
11. Liso-cel for large B-cell lymphoma is being developed by Bristol-Myers Squibb to treat large B-cell lymphomas, and a filing in the third-line setting is being ... Liso-cel (lisocabtagene maraleucel, JCAR-017) is an immunotherapy comprised of
-
Deal Watch January 2018
Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics portfolio incl JCAR017 (liso-cel), CD19-directed CAR-T in pivotal trials for DLBCL.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
Videum Health
Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
